Analyzing Galmed Pharmaceuticals (GLMD) & Its Peers
Galmed Pharmaceuticals (NASDAQ: GLMD) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Galmed Pharmaceuticals to similar businesses based on the strength of its earnings, valuation, dividends, risk, institutional ownership, profitability and analyst recommendations.
Risk and Volatility
Galmed Pharmaceuticals has a beta of 2.46, meaning that its share price is 146% more volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals’ competitors have a beta of 7.04, meaning that their average share price is 604% more volatile than the S&P 500.
Earnings & Valuation
This table compares Galmed Pharmaceuticals and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Galmed Pharmaceuticals||$470,000.00||-$16.95 million||-7.92|
|Galmed Pharmaceuticals Competitors||$284.49 million||$33.78 million||83.36|
Galmed Pharmaceuticals’ competitors have higher revenue and earnings than Galmed Pharmaceuticals. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares Galmed Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Galmed Pharmaceuticals Competitors||-5,311.79%||-218.25%||-39.47%|
Insider and Institutional Ownership
9.9% of Galmed Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.0% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 17.1% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This is a breakdown of recent ratings for Galmed Pharmaceuticals and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Galmed Pharmaceuticals Competitors||864||3218||11674||232||2.71|
Galmed Pharmaceuticals currently has a consensus price target of $20.75, indicating a potential upside of 136.06%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 45.24%. Given Galmed Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe Galmed Pharmaceuticals is more favorable than its competitors.
Galmed Pharmaceuticals competitors beat Galmed Pharmaceuticals on 7 of the 12 factors compared.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate, aramchol, is a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH). The Company’s Aramchol is a conjugate of cholic acid and arachidic acid, which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials.
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.